Contents
For patients
Autoinflammatory conditions: Patient Essentials
Start here for a clear overview of adult autoinflammatory conditions, with focused information on children and moving to adult care.
On this page
What are these conditions?
Autoinflammatory conditions cause excessive activity in part of the immune system. Fever, rash, pain and inflammation may recur, or inflammation may persist between episodes. Some conditions are inherited; others first appear in adulthood. They are not contagious.
Read how symptoms and diagnosis are assessed and which conditions affect adults.
Detailed chapters are free after registration. This Essentials overview remains open.
How are they diagnosed and treated?
There is no single test for the whole group. Clinicians use your history, examination, blood and urine tests, and sometimes genetic testing, imaging or a biopsy. Similar symptoms can come from infection or other diseases. Treatment depends on the diagnosis; it may include colchicine or medicines that block specific inflammatory signals.
Continue monitoring even when you feel better, and agree on a plan before changing medicine. See treatment and daily life.
What should I discuss with my team?
Ask what is confirmed, which organs need checks, how to manage a usual flare, when to seek urgent help and who reviews your results. Mention work or study, side effects, medicine costs, vaccination and pregnancy plans.
Severe breathing difficulty, collapse, confusion, new neurologic symptoms or severe new chest or abdominal pain need emergency assessment. Read the urgent-help guide.
Children and the move to adult care
Pediatric autoinflammatory disease is a separate topic. Our short pediatric guide covers the essentials. The transition guide explains how to keep medicines, records and follow-up connected when moving to adult care.
Sources and further reading
- EULAR/ACR: diagnosis, management and monitoring of CAPS, TRAPS, MKD and DIRA (2021 points to consider; published 2022)
- EULAR/PReS recommendations for FMF: 2024 update (published 2025)
- EULAR/PReS recommendations for Still’s disease (2024)
- EULAR/PReS standards for transition from pediatric to adult rheumatology (2017)